About ChemoCentryx
ChemoCentryx is a publicly listed company based in Mountain View (United States) founded in 1997, and was acquired by Amgen in August 2022. It operates as an orphan drugs for autoimmune, inflammatory, and rare diseases are developed. ChemoCentryx has raised $80.54 million across 5 funding rounds from investors including Amgen, Hercules Capital and Bio-Techne. The company has 178 employees. Its focus areas include Life Sciences, Immunology, Drugs and Diversified. Its legal entity is CHEMOCENTRYX, INC. Its competitors include Biogen, UCB, Grifols, Kymeratx and PureTech Health and 4 more; 7 of its 9 listed competitors have raised funding.
Company details
ChemoCentryx was founded in 1997 in Mountain View, United States, within the biotechnology sector. Orally administered small molecule therapeutics are discovered, developed, and commercialized for autoimmune diseases, inflammatory disorders, and cancer, with emphasis on orphan and rare conditions. Chemokine and chemoattractant receptors are targeted to inhibit immune system cascades. Clinical-stage products are advanced in phases 2 and 3 for kidney disease, immuno-oncology, Crohns disease, and other autoimmune indications.
- Headquarters Mountain View, United States
- Employees 178
- Stage Public
- SectorsHealthcare
- Website chemocentryx.com
- Social LinkedIn
- Acquired by Amgen (Aug 2022)
- Legal Name Chemocentryx Inc.
- Annual Revenue$32.22 M (USD)-50as on Dec 31, 2021
- Net Profit-$131.76 M (USD)-138as on Dec 31, 2021
- EBITDA-$129.92 M (USD)-135as on Dec 31, 2021
- Total Equity Funding$80.54M (USD)
in 5 rounds
- Latest Funding Round$1M (USD), Grant
Sep 2019
- InvestorsAmgen
& 9 more
- Employee Count178
- Acquired byAmgen
(Aug 2022)
Funding Insights of ChemoCentryx
ChemoCentryx has successfully raised a total of $80.54M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $1 million completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $80.54M
- Total Rounds 5
- Last Round Grant — $1M
- First Round $33M
(Jun 2004)
- Investors Count 9
All 5 funding rounds of ChemoCentryx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2019 | $1M | Grant | – | – | |
| Jan 2018 | $50M | Post-IPO | – | – | |
| Mar 2007 | $29.84M | Series C | – | – | |
| Aug 2006 | $17.7M | Series C | – | – | |
| Jun 2004 | $33M | Series B | – | – |
10 investors in total: 10 institutional.
Investors in ChemoCentryx
ChemoCentryx has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Amgen, Hercules Capital and Bio-Techne.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
Venture capital firm focused on healthcare companies | – | altapartners.com | Jackson, United States | |
Private equity firm | 1980 | gimv.com | Antwerp, Belgium | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
- | – | healthcap.eu | - | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Offers asset management and advisory for equities and fixed income portfolios. | 1969 | jennison.com | New York, United States | |
Developer of biotech reagents, instruments and clinical diagnostic products | 1981 | bio-techne.com | Minneapolis, United States | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | amgen.com | Thousand Oaks, United States |
Investor details for ChemoCentryx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ChemoCentryx
1108 people are tracked at ChemoCentryx (431 in leadership, 47 in board & advisors, 630 in team); the tracked headcount is 178.
| Name | Role | Group |
|---|---|---|
Seamus Lyons | Sr. Director Manufacturing | Leadership |
Alma Holden | Associate Director Validation | Leadership |
Francisco J Aguado-Rodriguez | Director Of Quality - Data Integrity And Ops Management Review GPO | Leadership |
Vivian Tu | Senior Director, Competitive Intelligence | Leadership |
Amro Essmat | Director , Quality - Regional Quality Head TMEA - Turkey, Middle East & Africa At Amgen | Leadership |
Miriam O'Sullivan | Executive Director Plant Manager | Leadership |
Mara Wachholder | Director, Treasury | Leadership |
Thiago Pastore | Human Resources Director, Brazil | Leadership |
Chris Pacheco | Director Manufacturing | Leadership |
Aditya Tulsyan | Associate Director Data Sciences, Operations | Leadership |
Andreas Reichelt | Senior Director Contract Manufacturing | Leadership |
Laura Cooke | Program Management Executive Director | Enterprise Transformation | Leadership |
Ned Endler | Executive Director US Trade, Channel Strategy And Execution | Leadership |
Amy Belisle | Associate Director Quality | Leadership |
Susie Tappouni | Head of Corporate Affairs | Leadership |
Kim Worrell | Associate Director HR Systems & Solutions | Leadership |
Jessica Vargas | Director, HR Business Partner | Leadership |
Mark Corder | Senior Director | Leadership |
Tara U. | Director, Global Corporate Affairs, Operations | Leadership |
Elena Pakhomov | Executive Director Of Sales | Leadership |
1088 more people are available in the full profile.
Complete people profiles for ChemoCentryx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of ChemoCentryx
ChemoCentryx is a publicly listed company on the NASDAQ with ticker symbol CCXI in USA, operating in the Finance sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date10 Feb 2012
- Listed onNASDAQ: CCXI
- Listed entityChemoCentryx Inc.
- Exchange sectorFinance
- ISINKYG2131A1085
- Share price$11.16 (+3.53% on the day) · 2026-10-13
- Market capitalisation$621.6M
- EPS (diluted, trailing year)$-2.35
- Volume (last session)2,581,017
Timeline of ChemoCentryx
5 dated milestones of ChemoCentryx across 25 years, from founding to its latest funding, stage changes and deals.
- Founded ChemoCentryx is founded.
- Funding First funding round of $33.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $1.0M.
- Exit Acquired by Amgen.
Competitors of ChemoCentryx
ChemoCentryx has 9 listed competitors in our database, 7 of them funded. They include Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| ucb.com | 1928 | Brussels, Belgium | – | 79 | Therapies for immunological and neurological disorders are developed. | |
| grifols.com | 1909 | Barcelona, Spain | – | 18,309 | Plasma-derived therapies are developed to treat multiple diseases. | |
| kymeratx.com | 2016 | Cambridge, United States | $197M | 150 | Small molecule protein degraders are developed for various disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. | |
| generatebiomedicines.com | 2018 | Somerville, United States | $643M | 286 | Developer of novel protein-based therapeutics using machine learning and biological engineering | |
| portola.com | 2003 | San Francisco, United States | $296.09M | 369 | Therapeutics for cardiovascular and autoimmune diseases are developed. | |
| biontech.com | 2008 | Mainz, Germany | $805.99M | 4,530 | Immunotherapeutics for cancer and other diseases are developed. | |
| admabiologics.com | 2005 | Ramsey, United States | $17.55M | 498 | Plasma-based biologics are developed for immune deficiency and infectious diseases. |
Detailed competitors of ChemoCentryx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ChemoCentryx
Websites that share an audience with ChemoCentryx (chemocentryx.com).
Websites whose visitors overlap most with ChemoCentryx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| incyte.com | 100% | 82.2K | #247,619 | View details | |
| illumina.com | 100% | 672.7K | #61,793 | View details |
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as ChemoCentryx (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Chemocentryx
Complete news archive for ChemoCentryx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ChemoCentryx
ChemoCentryx was founded in 1997 and raised its 1st funding round 7 years after it was founded.
ChemoCentryx is headquartered in Mountain View, United States. It is registered at Mountain View, California, United States.
ChemoCentryx is a funded company, having raised a total of $80.54M across 5 funding rounds to date. The company's 1st funding round was a Series B of $33M, raised on Jun 2004.
ChemoCentryx has 178 employees.
Annual revenue of ChemoCentryx is $32.22M as on Dec 31, 2021.
ChemoCentryx was founded in 1997 in Mountain View, United States, within the biotechnology sector. Orally administered small molecule therapeutics are discovered, developed, and commercialized for autoimmune diseases, inflammatory disorders, and cancer, with emphasis on orphan and rare conditions. Chemokine and chemoattractant receptors are targeted to inhibit immune system cascades. Clinical-stage products are advanced in phases 2 and 3 for kidney disease, immuno-oncology, Crohns disease, and other autoimmune indications.
ChemoCentryx's top competitors include ADMA Biologics, BioNTech and Generate Biomedicines.
Yes, ChemoCentryx is publicly traded on NASDAQ under the ticker symbol CCXI.
ChemoCentryx has 10 investors. Key investors include Amgen, Hercules Capital, Bio-Techne, HHS, and Orbimed.
ChemoCentryx operates through Chemocentryx, Inc..
Yes. ChemoCentryx was acquired by Amgen in August 2022.